Skip to main content

Table 3 Distribution of treatments according to molecular diagnosis

From: Clinical and economic impact of current ALK rearrangement testing in Spain compared with a hypothetical no-testing scenario

Molecular diagnosis Treatment Distribution
BC SA
ALK+ Alectinib 89.38% 80%
Crizotinib 10.63% 20%
EGFR+ Erlotinib 15.0% 0.0%
Gefitinib 30.0% 30.0%
Afatinib 15.0% 5.0%
Osimertinib 40.0% 65.0%
ROS1+ Crizotinib 100% 100%
WT TPS 50% Pembrolizumab 100% 100%
TPS < 50% Cisp + pmtrx 30.00% 40.0%
Carb+ paclitx + bev 10.00% 5.0%
Cisp + pmtrx + pembro 60.00% 55.0%
  1. ALK anaplastic lymphoma kinase, EGFR epidermal growth factor receptor, WT wild-type, TPS tumor proportion score, Cisp cisplatin, Carb carboplatin, pmtrx pemetrexed, paclitx paclitaxel, bev bevacizumab, BC Base case, SA sensitivity analysis